臨床眼科74巻13号

2020年12月発行

連載 今月の話題

遺伝性網膜疾患に対する遺伝子治療

著者： 藤波芳¹²³⁴ 藤波優¹³⁵⁶ 鈴木泰賢¹

所属機関： ¹国立病院機構東京医療センター臨床研究センター視覚研究部視覚生理学研究室 ²慶応義塾大学医学部眼科学教室 ³UCL Institute of Ophthalmology（英国） ⁴Division of Inherited Eye Disease, Medical Retina, Moorfields Eye Hospital（英国） ⁵慶應義塾大学大学院健康マネジメント研究科 ⁶慶應義塾大学医学部医療政策管理学教室

ページ範囲：P.1472 - P.1483

　遺伝性網膜疾患（IRD）は，現在先進国最大の失明原因となっている。わが国では，根本治療アプローチが存在せず，IRDに対する正確な診断および新規根本治療の導入が急務である。このような状況のなか，近年では欧米を中心としたIRDに対する治療法の開発が目覚ましい。本稿では，IRDの基礎知識，遺伝子治療・その他の治療，診断から治療へのアプローチについて，最新の知見を含めて紹介する。

参考文献

1）Sohocki MM, Daiger SP, Bowne SJ et al：Prevalence of mutations causing retinitis pigmentosa and other inherited retinopathies. Hum Mutat 17：42-51, 2001

2）Liew G, Michaelides M, Bunce C：A comparison of the causes of blindness certifications in England and Wales in working age adults（16-64 years）, 1999-2000 with 2009-2010. BMJ Open 4. doi：10.1136/bmjopen-2013-004015, 2016

3）網膜色素変性診療ガイドライン作成ワーキンググループ：網膜色素変性診療ガイドライン．日眼会誌120：846-861，2016

4）角田和繁：網脈絡膜ジストロフィの遺伝学的病態解明および治療に向けた症例データバンクの構築．日眼会誌124：247-284，2020

5）藤波　芳：遺伝性網膜疾患の現状と展望．医療70：282-287，2016

6）藤波　芳・藤波　優・Lizhu Yang・他：黄斑ジストロフィの分子病態．眼科60：309-321，2018

7）Smith J, Ward D, Michaelides M et al：New and emerging technologies for the treatment of inherited retinal diseases：a horizon scanning review. Eye（Lond） 29：1131-1140, 2015

8）Scholl HP, Strauss RW, Singh MS et al：Emerging therapies for inherited retinal degeneration. Sci Transl Med. doi：10.1126/scitranslmed.aaf2838, 2016

9）藤波　芳：ゲノム情報と国内・国際ネットワーク．あたらしい眼科34：71，2017

10）Liu X, Fujinami-Yokokawa Y, Yang L, et al：Stargardt disease in Asian population. In：Prakash G, Iwata T（eds）：Advances in Vision Research, Volume Ⅱ. 279-296, Springer, Berlin, 2018

11）Wang D, Gao G：State-of-the-art human gene therapy：part Ⅱ. Gene therapy strategies and clinical applications. Discov Med 18：151-161, 2014

12）Riccardo S, Scott H, Wagner N et al：Genetic testing of various eye disorders. In：Gao XR（ed）：Genetics and Genomics of Eye Disease. Advancing to Precision Medicine. 239-258, Elsevier, Amsterdam, 2019

13）Lam BL：Update on gene therapy for the treatment of hereditary retinal diseases. Retina Today：66-71, 2017

14）Vázquez-Domínguez I, Garanto A, Collin RWJ：Molecular therapies for inherited retinal diseases-current standing, opportunities and challenges. Genes（Basel） 10. doi：10.3390/genes10090654, 2019

15）Iwanami M, Oshikawa M, Nishida T et al：High prevalence of mutations in the EYS gene in Japanese patients with autosomal recessive retinitis pigmentosa. Invest Ophthalmol Vis Sci 53：1033-1040, 2012

16）Oishi M, Oishi A, Gotoh N et al：Comprehensive molecular diagnosis of a large cohort of Japanese retinitis pigmentosa and Usher syndrome patients by next-generation sequencing. Invest Ophthalmol Vis Sci 55：7369-7375, 2014

17）Arai Y, Maeda A, Hirami Y et al：Retinitis pigmentosa with EYS mutations is the most prevalent inherited retinal dystrophy in Japanese populations. J Ophthalmol. doi：10.1155/2015/819760, 2015

18）Kong X, Strauss RW, Michaelides M et al：Visual acuity loss and associated risk factors in the retrospective progression of Stargardt disease study（ProgStar Report No. 2）. Ophthalmology 123：1887-1897, 2016

19）Strauss RW, Ho A, Muñoz B et al：The natural history of the progression of atrophy secondary to stargardt disease（ProgStar）studies：design and baseline characteristics：ProgStar Report No. 1. Ophthalmology 123：817-828, 2016

20）Carss KJ, Arno G, Erwood M et al：Comprehensive rare variant analysis via whole-genome sequencing to determine the molecular pathology of inherited retinal disease. Am J Hum Genet 100：75-90, 2017

21）Stone EM, Andorf JL, Whitmore SS et al：Clinically focused molecular investigation of 1000 consecutive families with inherited retinal disease. Ophthalmology 124：1314-1331, 2017

22）Hosono K, Nishina S, Yokoi T et al：Molecular diagnosis of 34 Japanese families with Leber congenital amaurosis using targeted next generation sequencing. Sci Rep. doi：10.1038/s41598-018-26524-z, 2018

23）Kong X, Fujinami K, Strauss RW et al：Visual acuity change over 24 months and its association with foveal phenotype and genotype in individuals with Stargardt disease：ProgStar Study Report No. 10. JAMA Ophthalmol 136：920-928, 2018

24）Maeda A, Yoshida A, Kawai K et al：Development of a molecular diagnostic test for retinitis pigmentosa in the Japanese population. Jpn J Ophthalmol 62：451-457, 2018

25）Messchaert M, Haer-Wigman L, Khan MI et al：EYS mutation update：In silico assessment of 271 reported and 26 novel variants in patients with retinitis pigmentosa. Hum Mutat 39：177-186, 2018

26）Fujinami K, Strauss RW, Chiang JP et al：Detailed genetic characteristics of an international large cohort of patients with Stargardt disease：ProgStar study report 8. Br J Ophthalmol 103：390-397, 2019

27）Iwanami M, Oishi A, Ogino K et al：Five major sequence variants and copy number variants in the EYS gene account for one-third of Japanese patients with autosomal recessive and simplex retinitis pigmentosa. Mol Vis 25：766-779, 2019

28）Kondo H, Oku K, Katagiri S et al：Novel mutations in the RS1 gene in Japanese patients with X-linked congenital retinoschisis. Hum Genome Var. doi：10.1038/s41439-018-0034-6, 2019

29）Koyanagi Y, Akiyama M, Nishiguchi KM et al：Genetic characteristics of retinitis pigmentosa in 1204 Japanese patients. J Med Genet 56：662-670, 2019

30）Fujinami-Yokokawa Y, Pontikos N, Yang L et al：Prediction of causative genes in inherited retinal disorders from spectral-domain optical coherence tomography utilizing deep learning techniques. J Ophthalmol. doi：10.1155/2019/1691064, 2019

31）Fujinami K, Yang L, Joo K et al：Clinical and genetic characteristics of east asian patients with occult macular dystrophy（Miyake disease）：east asia occult macular dystrophy studies report number 1. Ophthalmology 126：1432-1444, 2019

32）Kameya S, Fujinami K, Ueno S, et al：Phenotypical characteristics of POC1B-Associated retinopathy in Japanese cohort：cone dystrophy with normal funduscopic appearance. Invest Ophthalmol Vis Sci 60：3432-3446, 2019

33）Nakamura N, Tsunoda K, Mizuno Y et al：Clinical stages of occult macular dystrophy based on optical coherence tomographic findings. Invest Ophthalmol Vis Sci 60：4691-4700, 2019

34）Liu X, Fujinami K, Kuniyoshi K et al：Clinical and genetic characteristics of 15 affected patients from 12 Japanese families with GUCY2D-associated retinal disorder. Transl Vis Sci Technol（In press）

35）Yang L, Fujinami K, Ueno S et al：Genetic spectrum of EYS-associated retinal disease in a large Japanese cohort：Identification of Disease-associated Variants with Relatively High Allele Frequency. Sci Rep（In press）

36）Kaur C, Foulds WS, Ling EA：Blood-retinal barrier in hypoxic ischaemic conditions：basic concepts, clinical features and management. Prog Retin Eye Res 27：622-647, 2008

37）Anand V, Duffy B, Yang Z et al：A deviant immune response to viral proteins and transgene product is generated on subretinal administration of adenovirus and adeno-associated virus. Mol Ther 5：125-132, 2002

38）Bennett J：Immune response following intraocular delivery of recombinant viral vectors. Gene Ther 10：977-982, 2003

39）Liang FQ, Anand V, Maguire AM et al：Intraocular delivery of recombinant virus. Methods Mol Med 47：125-139, 2001

40）Soofiyani SR, Baradaran B, Lotfipour F et al：Gene therapy, early promises, subsequent problems, and recent breakthroughs. Adv Pharm Bull 3：249-255, 2013

41）Arbabi A, Liu A, Ameri H：Gene Therapy for Inherited Retinal Degeneration. J Ocul Pharmacol Ther 35：79-97, 2019

42）Lewin AS, Rossmiller B, Mao H：Gene augmentation for adRP mutations in RHO. Cold Spring Harb Perspect Med. doi：10.1101/cshperspect.a017400, 2014

43）Rowe-Rendleman CL, Durazo SA, Kompella UB et al：Drug and gene delivery to the back of the eye：from bench to bedside. Invest Ophthalmol Vis Sci 55：2714-2730, 2014

44）Sanjurjo-Soriano C, Kalatzis V：Guiding lights in genome editing for inherited retinal disorders：implications for gene and cell therapy. Neural Plast. doi：10.1155/2018/5056279, 2018

45）Slaymaker IM, Gao L, Zetsche B et al：Rationally engineered Cas9 nucleases with improved specificity. Science 351：84-88, 2016

46）Diakatou M, Manes G, Bocquet B et al：Genome editing as a treatment for the most prevalent causative genes of autosomal dominant retinitis pigmentosa. Int J Mol Sci. doi：10.3390/ijms20102542, 2019

47）Maeder ML, Stefanidakis M, Wilson CJ et al：Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. Nat Med 25：229-233, 2019

48）Simunovic MP, Shen W, Lin JY et al：Optogenetic approaches to vision restoration. Exp Eye Res 178：15-26, 2019

49）Yue L, Weiland JD, Roska B et al：Retinal stimulation strategies to restore vision：fundamentals and systems. Prog Retin Eye Res 53：21-47, 2016

50）Tomita H, Sugano E, Isago H et al：Channelrhodopsin-2 gene transduced into retinal ganglion cells restores functional vision in genetically blind rats. Exp Eye Res 90：429-436, 2010

51）Tomita H, Sugano E, Murayama N et al：Restoration of the majority of the visual spectrum by using modified Volvox channelrhodopsin-1. Mol Ther 22：1434-1440, 2014

52）Tomita H, Sugano E, Yawo H et al：Restoration of visual response in aged dystrophic RCS rats using AAV-mediated channelopsin-2 gene transfer. Invest Ophthalmol Vis Sci 48：3821-3826, 2007

53）Ahnelt PK, Kolb H：The mammalian photoreceptor mosaic-adaptive design. Prog Retin Eye Res 19：711-777, 2000

54）Liu MM, Zack DJ：Alternative splicing and retinal degeneration. Clin Genet 84：142-149, 2013

55）Nagel-Wolfrum K, Möller F, Penner I et al：Targeting nonsense mutations in diseases with translational read-through-inducing drugs（TRIDs）. BioDrugs 30：49-74, 2016

56）Moosajee M, Tracey-White D, Smart M et al：Functional rescue of REP1 following treatment with PTC124 and novel derivative PTC-414 in human choroideremia fibroblasts and the nonsense-mediated zebrafish model. Hum Mol Genet 25：3416-3431, 2016

57）Torriano S, Erkilic N, Baux D et al：The effect of PTC124 on choroideremia fibroblasts and iPSC-derived RPE raises considerations for therapy. Sci Rep. doi：10.1038/s41598-018-26481-7, 2018

58）Sarkar H, Mitsios A, Smart M et al：Nonsense-mediated mRNA decay efficiency varies in choroideremia providing a target to boost small molecule therapeutics. Hum Mol Genet 28：1865-1871, 2019

59）Faber S, Roepman R：Balancing the photoreceptor proteome：proteostasis network therapeutics for inherited retinal disease. genes（Basel）. doi：10.3390/genes10080557, 2019

60）Parfitt DA, Aguila M, McCulley CH et al：The heat-shock response co-inducer arimoclomol protects against retinal degeneration in rhodopsin retinitis pigmentosa. Cell Death Dis. doi：10.1038/cddis.2014.214, 2014

61）Athanasiou D, Aguila M, Bellingham J et al：The molecular and cellular basis of rhodopsin retinitis pigmentosa reveals potential strategies for therapy. Prog Retin Eye Res 62：1-23, 2018

62）Kubota R, Gregory J, Henry S et al：Pharmacotherapy for metabolic and cellular stress in degenerative retinal diseases. Drug Discov Today 25：292-304, 2020

63）Hussain RM, Ciulla TA, Berrocal AM et al：Stargardt macular dystrophy and evolving therapies. Expert Opin Biol Ther 18：1049-1059, 2018

64）Scholl HP, Moore AT, Koenekoop RK et al：Safety and proof-of-concept study of Oral QLT091001 in retinitis pigmentosa due to inherited deficiencies of retinal pigment epithelial 65 protein（RPE65）or lecithin：retinol acyltransferase（LRAT）. PLoS One. doi：10.1371/journal.pone.0143846, 2015

65）Richards S, Aziz N, Bale S et al：Standards and guidelines for the interpretation of sequence variants：a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17：405-424, 2015